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INTRODUCTION
An estimated 350 million persons worldwide are
chronically infected with hepatitis B virus (HVB), and
170 millions are chronically infected by hepatitis C
virus (HCV).1 Carriers of hepatitis virus are at
increased risk of developing cirrhosis, hepatic
decompensation/insufficiency hemorrhage, and
hepatocellular carcinoma/HCC.2 Although most
carriers will not develop hepatic complications, some
will develop serious sequels during their life time.
Staging hepatic fibrosis by liver biopsy is necessary to
guide prognosis and treatment in chronic hepatitis, and
recommendation in the guideline pertain to evaluation
of patients with chronic infection periodically.3 Although
liver biopsy is the gold standard for assessment of
hepatic fibrosis.4,5,6 It has several disadvantages, such
as invasive, poor patient compliance, the risk of poorly
standardized collection of liver tissues, sampling error,
limited usefulness for dynamic surveillance and
follow up, and poor intra and inter-observation
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ABSTRACT
Progressive liver fibrosis with development of cirrhosis is a feature of almost all chronic liver diseases.
Carriers of hepatitis B and C virus are at increased risk of developing cirrhosis, hepatic decompensation/
insufficiency, hemorrhage, and hepatocellular carcinoma (HCC). Therefore, periodic evaluations of these
patients are necessary. Fibrosis is deleterious but variable consequence of chronic inflammation. It is
characterized by deposition of extra cellular matrix component leading to distortion of hepatic
architecture with impairment of liver microcirculation and liver cell function. Although liver biopsy is
the gold standard for assessment of liver fibrosis, it has several disadvantages. Considering these
limitations and patient redundancy to undergo liver biopsy, it is vital that non-invasive predictors/
methods for assessment of liver fibrosis be developed and validated. Application of this method could be
used to evaluate the efficacy of treatment, which is a simple and meaningful way.
Recently, clinical investigators have been searching for noninvasive serum markers of fibrosis, which
have the following characteristics: they must be reliable, accurate, reproducible and easy to perform.
Several markers or combination of several markers have shown promise for the detection of advanced
fibrosis, although their sensitivities for detecting milder fibrosis are poor. Non-invasive laboratory
bio-markers of liver fibrosis might be applied to patients who either have contra-indication or refuse liver
biopsy for management of their chronic liver diseases.
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concordance.5,6,7 Considering these limitations and
patient redundancy to undergo liver biopsy, noninvasive
predictors of liver histology are urgently needed.
Recently, clinical investigators have been searching for
noninvasive serum markers of fibrosis which have
the following characteristics, i.e. they must be reliable,
accurate, reproducible, and easy to perform.8 Routinely
measured serum markers, have been examined as
alternative for staging fibrosis among chronic
hepatitis. So far, no single serum marker has been able
to correctly diagnose and assess the degree and
progression of hepatic fibrosis. A combination of
reliable, noninvasive serum markers were developed
to predict fibrosis and assess prognosis and treatment
of liver fibrosis.7
PATHOGENESIS OF LIVER FIBROSIS
Activity and fibrosis are two major histological
features of chronic hepatitis. Fibrosis is deleterious but
variable consequence of chronic inflammation. It is
characterized by deposition of extra cellular matrix
component leading to distortion of hepatic architecture
with impairment of liver microcirculation and liver cell
function.2
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Extra cellular matrix deposition is consecutive to
the activity of fibrogenic cells known as liver
myofibroblasts. Myofibroblasts are almost absent from
the normal liver, they derive from activation of
precursor cells, the best studied being hepatic stellate
cells.5 Hepatic stellate cells are probably “resting
pericyte” and do not proliferate, which can be rapidly
activated, acquiring contractile properties which in turn
can regulate local blood pressure. It is increasingly
recognized that HCV can directly exert profibrogenic
effect on the liver.
Hypothesis on the occurrence of liver fibrosis are
as follows: (1) Recurrent necrosis and regeneration
will stimulate the activation of hepatic stellate cells.
(2) Activation of hepatitis stellate cells (HSCs)
resulting in increased proliferation, and release of
profibrogenic cytokines (e.g. TGF-beta, PDGF, etc)
by sensitized T lymphocyte and monocytes (by virus).
(3) Hepatic stellate cells then will differentiate to cells
resemble to myofibroblast, so that it will increase
synthesis of contractile matrix protein, enhancement
of type I collagen secretion and development of liver
fibrosis.2
Several factors have been shown to be associated
with fibrosis progression rate, e.g. duration of
 infection, age, male, gender, heavy consumption of
alcohol, human immunodeficiency virus (HIV),
co-infection, low CD4 count, and necrosis grade.2
The progression from infection to cirrhosis depends
strongly on age as expressed by duration of infection,
age of infection, or age at last biopsy. Metabolic condi-
tion such as overweight, steatosis, and diabetes are
emerging as independent co-factors of fibrogenesis.2
There is a strong correlation for fibrosis stages, that
almost linear with age at biopsy and duration of
infection. Distribution of fibrosis progression rate
suggests the presence of at least three populations:
a population of rapid fibrosers, a population of
intermediate fibrosers and a population of slow
fibrosers.
Using median fibrosis progression rate, in untreated
patients, the median expected time to cirrhosis is
30 years.2 Infection by HCV is usually lethal when it
lead to cirrhosis, the last stage of liver fibrosis,
therefore an estimate of fibrosis progression represent
an important surrogate end-point for evaluation of
vulnerability of an individual, and for assessment of
treatment impact on natural history.
SERUM MARKERS TO CHARACTERIZE LIVER
FIBROSIS
Liver fibrosis is the main complication of all chronic
liver diseases with progression to cirrhosis as its
end-stage clinical expression. Information and
knowledge about the stage of liver fibrosis is essential
for prognostication and decisions on antiviral treatment
in chronic hepatitis B and C.9 Several predictive
indices using more commonly performed laboratory
tests have been proposed. Model for predicting both
significant fibrosis and cirrhosis included platelets count,
aspartate aminotransferase (AST), and alkaline
phosphatase with an area under ROC curve (AUC)
of 0.82 and 0.92 respectively.9 A novel index
consisting two readily available laboratory results: AST
to platelet ratio index (APRI) was developed to
amplify the opposing effects of liver fibrosis on AST
and platelet count. The area under ROC of APRI for
predicting significant fibrosis and cirrhosis were 0.80
and 0.89 respectively in the training set, and in the
validation set were 0.88 and 0.94 respectively.9
Informative serum markers (fibrosis index) were
developed lately to assess significant fibrosis of the
liver and cirrhosis. The most informative markers were
Alpha 2 macroglobulin, alpha 2 globulin (or
haptoglobin) gamma globulin, apolipoprotein A1, gamma
glutamyltranspeptidase and total bilirubin.10
FIBROTEST is the most frequently described test
proposed by Poynard’s team, provide a liver fibrosis
index which results from combination of 5 (five)
biological markers synthesized by the liver: alpha 2
macroglobulin, haptoglobin, apolipoprotein A1, total
bilirubin and gamma glutamyl-transpeptidase.
The ACTITEST, L-alanine aminotransferase (ALT)
is added, allowing the assessment of necro-
inflammatory histological activity.12 The fibrotest score
ranging from 0 to 1, is correlated with the Metavir stage
of fibrosis, with a positive predictive value > 90% for
score between 0.60 to 1 (definite presence of F2, F3
or F4 fibrosis stages), and a negative predictive value
= 100% for score ranging from 0 to 0.10 (definite
absence of F2, F3 or F4 stages of fibrosis). So, fibrotest
is an important tool for non-invasive evaluation of liver
fibrosis.11
HEPASCORE: Another accurate validated
predictor of liver fibrosis in chronic hepatitis C
infection. It is as model of 4 (four) serum markers
(bilirubin, gamma glutamyltransferase, hyaluronic acid,
alpha 2 macroglobulin) plus age and sex, which
produced areas under the ROI curve (AUC) of 0.85,
0.96 and 0.94 for significant fibrosis, advanced fibrosis
and cirrhosis respectively.6
To conclude, application of these parameters:
Fibrotest, as well Hepascore as a real alternative to
liver biopsy still requires standardization of
measurement methods and validation in a larger
number of chronic hepatitis C. A number of other
markers associated with matrix deposition could also
be used, such as hyalunionic acid (HA), type III
pro-collagen, (PC III), Laminin (LN) and type IV
collagen (C IV), but they can be influenced by the grade
of inflammation, some liver function indexes, and
clinical manifestations. A comprehensive analysis is
necessary for this purpose and requires further
validation.14
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CONCLUSION
Non-invasive laboratory bio-markers of liver
fibrosis alternative to liver biopsy have been developed
and validated. Combination of several laboratory
markers of liver fibrosis may be promising to improved
diagnostic accuracy.
Non-invasive markers of liver fibrosis will likely
reduce but not substitute the need for liver biopsy. They
should be considered as supportive toward
the common goal of correct classifying the stage of
liver fibrosis.
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